← Back to Clinical Trials
Recruiting NCT06839768

Safety and Efficacy of MILEP Versus Standard EEP

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Benign Prostate Hypertrophy(BPH)
Sponsor Sechenov University
Study Type INTERVENTIONAL
Phase N/A
Enrollment 340
Sex MALE
Min Age 18 Years
Max Age 85 Years
Start Date 2024-03-14
Completion 2025-03
Interventions
Standard endoscopic enucleation of the prostate (EEP)MiLEP

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Endoscopic enucleation of the prostate (EEP) is a standard treatment for benign prostatic hyperplasia (BPH), with modifications such as MiLEP that utilizes smaller instruments. The reduced resectoscope diameter in MiLEP may help decrease rates of stress urinary incontinence (SUI) and urethral strictures. Objective: to compare the efficacy and safety of MiLEP and standard EEP with a thulium fiber laser (TFL).

Eligibility Criteria

Inclusion Criteria: LUTS presence, proven by: 1. IPSS questionnaire (Score \>20); 2. OR uroflowmetry result (Qmax \<10 ml/s); Exclusion Criteria: * Prostate volume \> 120 cc * Prostate cancer on pathology; * Urethral strictures; * Bladder calculi; * Prior prostate surgery; * Neurogenic bladder dysfunction.

Related Trials

VIEW ON CLINICALTRIALS.GOV ↗ MORE BENIGN PROSTATE HYPERTROPHY(BPH) TRIALS
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}